ライフサイエンスコーパス: dextromethorphan

1 - clonidine and opioids; third, nystagmus - dextromethorphan.

2 preparations, particularly those containing dextromethorphan.

3 tors: mecamylamine, ketamine, bupropion, and dextromethorphan.

4 ioids, antidepressants, and the antitussive, dextromethorphan.

5 01 with METH (0.1-100 microM) did not reduce dextromethorphan (1 mM)-displaceable ligand binding.

6 Dextromethorphan (116.2% [104.6 to 129.1]), tolbutamide

7 The NMDA receptor blocker dextromethorphan (150 mg) suppressed the reduction in IC

8 old for SN; 20 mg/kg no effect) and 40 mg/kg dextromethorphan (3.4-fold for CS, 6.2-fold for SN, in 6

9 elective and competitive NMDA antagonist, or dextromethorphan (5-15 mg/kg, s.c.), a noncompetitive NM

10 dent plasticity was reduced substantially by dextromethorphan (an N-methyl-d-aspartate receptor block

11 Dextromethorphan, an antitussive agent with NMDA recepto

12 e oral dose of two anti-glutamatergic drugs (dextromethorphan, an NMDA receptor antagonist; perampane

13 articipants were given probe drugs (30 mg of dextromethorphan and 2 mg of alprazolam) to establish ba

14 The present study investigated the effect of dextromethorphan and 6,7-dinitroquinoxaline-2,3-dione (D

15 All individuals were also given liquid dextromethorphan and albuterol inhaler with a spacer.

16 capture and release of two guest molecules, dextromethorphan and beta-estradiol, which are widely fo

17 The maximum sampling rate was 6 Hz for dextromethorphan and d(3)-dextrorphan (each 100 nM) for

18 several drugs with known efficacy, including dextromethorphan and galantamine, and new drugs such as

19 Since dextromethorphan and metformin are two safe FDA-approved

20 In multiple ESCC mouse models, dextromethorphan and metformin synergistically repressed

21 ptake inhibitors, and a new agent containing dextromethorphan and quinidine.

22 The NMDA antagonist dextromethorphan and the non-NMDA (AMPA/kainate) antagon

23 by the noncompetitive antagonists MK-801 and dextromethorphan and were dependent on extracellular cal

24 ine, 20 mg omeprazole, 25 mg losartan, 30 mg dextromethorphan, and 2 mg midazolam.

25 ts, the bitter tastants denatonium, quinine, dextromethorphan, and noscapine, dose-dependently relaxe

26 enzymes (caffeine, tolbutamide, omeprazole, dextromethorphan, and oral and intravenous midazolam) wa

27 ate (NMDA) receptor (e.g., ketamine, MK-801, dextromethorphan, and phencyclidine) produce analgesia b

28 end of abuse of certain preparations such as dextromethorphan, and specific cases of morbidity and ev

29 Two such agents, memantine and dextromethorphan, are already in widespread clinical use

30 cations is demonstrated in this report using dextromethorphan as a model compound.

31 nts were randomly assigned to receive either dextromethorphan-bupropion (45 mg/105 mg tablet) or bupr

32 In patients with major depression, dextromethorphan-bupropion (AXS-05) significantly improv

33 ore from baseline) at week 6 were 60.5% with dextromethorphan-bupropion and 40.5% with bupropion (lea

34 ission rates were significantly greater with dextromethorphan-bupropion at week 2 and every time poin

35 epressants (e.g., esketamine nasal spray and dextromethorphan-bupropion combination) and several more

36 2 trial assessed the efficacy and safety of dextromethorphan-bupropion in the treatment of major dep

37 tment effect) was significantly greater with dextromethorphan-bupropion than with bupropion (-13.7 po

38 multicenter, parallel-group trial evaluated dextromethorphan-bupropion versus the active comparator

39 Dextromethorphan-bupropion was not associated with psych

40 MADRS score change with dextromethorphan-bupropion was significantly greater tha

41 The most common adverse events with dextromethorphan-bupropion were dizziness, nausea, dry m

42 AXS-05 (dextromethorphan-bupropion) is an oral NMDA receptor ant

43 g in 80 patients in the efficacy population (dextromethorphan-bupropion, N=43; bupropion, N=37).

44 Most secondary outcomes favored dextromethorphan-bupropion.

45 significantly reduced by pre-treatment with dextromethorphan but not DNQX.

46 Neither LY 2359595 nor dextromethorphan by itself significantly altered body te

47 Dextromethorphan causes alterations in mental status tha

48 EP peaks were not reliably altered following dextromethorphan compared to placebo, although findings

49 The recent trend of prescription and dextromethorphan-containing over-the-counter medication

50 ne [probe for CYP1A2], tolbutamide [CYP2C9], dextromethorphan [CYP2D6], midazolam [CYP3A4], and digox

51 enzyloxy-4-trifluoromethylcoumarin (BFC) and dextromethorphan (DEX).

52 However, healthy participants receiving dextromethorphan displayed a jumping-to-conclusions bias

53 ABA(A) receptor agonist) relative to that of dextromethorphan (DM) (an NMDA receptor antagonist) and

54 d the neuroprotective property of analogs of dextromethorphan (DM) in lipopolysaccharide (LPS) and 1-

55 ersus combined treatment of melatonin and/or dextromethorphan (DM), a clinically available N-methyl-d

56 sly showed that micromolar concentrations of dextromethorphan (DM), a major ingredient of widely used

57 We recently reported that dextromethorphan (DM), a widely used anti-tussive agent,

58 We recently reported that dextromethorphan (DM), an active ingredient in a variety

59 receptor agonists/antagonists (D-cycloserine/dextromethorphan), dopamine type 2 receptor agonists/ant

60 noticed that, in vivo, the NMDAR antagonist dextromethorphan (DXM) enhanced glucose tolerance in mic

61 sult of NMDA receptor antagonism with 120 mg dextromethorphan [F(1,34) = 5.291, P = 0.028].

62 chlorpromazine, promethazine, procaine, and dextromethorphan, frequently used cutting agents in coca

63 -1), with a relative order of mecamylamine > dextromethorphan > or = ketamine > bupropion.

64 Accordingly, denatonium, quinine and dextromethorphan increased intracellular calcium concent

65 Dextromethorphan increased the amplitude of the N45 TEP,

66 lues determined in this study indicated that dextromethorphan-induced inhibition should produce a lon

67 Suppression due to procaine and dextromethorphan is caused by fouling of the electrode s

68 Pharmacodynamic interactions with dextromethorphan may produce serotonin syndrome.

69 ed before and after administration of either dextromethorphan (NMDA receptor antagonist) or placebo a

70 Mechanistically, dextromethorphan non-competitively inhibited nicotine bi

71 found to metabolize xenobiotics carrying out dextromethorphan O- and N-demethylations, diclofenac 4'-

72 The primary effect of dextromethorphan, (+)-pentazocine, (+)-cyclazocine, (+)-

73 response and rerandomized in a 1:1 ratio to dextromethorphan-quinidine (n = 59) or placebo (n = 60).

74 ts were randomized in a 3:4 ratio to receive dextromethorphan-quinidine (n = 93) or placebo (n = 127)

75 lel comparison design, 152 patients received dextromethorphan-quinidine and 127 received placebo duri

76 ion scores were reduced from 5.8 to 3.8 with dextromethorphan-quinidine and from 6.7 to 5.8 with plac

77 ion scores were reduced from 7.1 to 3.8 with dextromethorphan-quinidine and from 7.0 to 5.3 with plac

78 In stage 2, patients receiving dextromethorphan-quinidine continued; those receiving pl

79 with probable Alzheimer disease, combination dextromethorphan-quinidine demonstrated clinically relev

80 Adverse events included falls (8.6% for dextromethorphan-quinidine vs 3.9% for placebo), diarrhe

81 Serious adverse events occurred in 7.9% with dextromethorphan-quinidine vs 4.7% with placebo.

82 reduced NPI Agitation/Aggression scores for dextromethorphan-quinidine vs placebo (ordinary least sq

83 Dextromethorphan-quinidine was not associated with cogni

84 In vivo, MK-801 and dextromethorphan reduce methamphetamine-induced activati

85 hereas the PCP-related sigma ligands such as dextromethorphan, (+)-SKF10047 and (+)-cyclazocine were

86 The mean (SD) urinary ratio of dextromethorphan to its metabolite was 0.006 (0.010) at

87 ults indicate that the ability of MK-801 and dextromethorphan to protect against methamphetamine neur

88 not significantly affected, whereas block by dextromethorphan was increased (N615K [n=9], 56% [8] vs

89 Using pcSFC and MS/MS, dextromethorphan was quantified in 96-well plates at a r

90 The non-opioid antitussive, dextromethorphan, which has been shown to inhibit glutam